Open access
Oct 2026
Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6-18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial.
BACKGROUND Respiratory syncytial virus (RSV) causes acute respiratory illness in young children. The live-attenuated RSV vaccine candidate RSV/ΔNS2/Δ1313/I1314L (RSVt) has shown promising immunogenicity and safety in children aged 6-18 months. However, how baseline RSV serostatus influences immunogenicity and viral she...
O. Idoko, Sergio L. Vargas, Agustin Bueso et al.
· The Lancet Microbe · 0 citations